Revolutionizing Diagnosis and Treatment: Adaptive Biotechnologies’ Business Update

Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Scheduled for April 2, 2024

Adaptive Biotechnologies Corporation is a biotechnology company listed on the Nasdaq under the ticker symbol ADPT. The company’s mission is to harness the power of the adaptive immune system to revolutionize disease diagnosis and treatment. Through its immune medicine platform, Adaptive Biotechnologies decodes the genetics of the adaptive immune system with speed, precision, and scale, enabling it to collaborate with biopharmaceutical companies and inform drug development.

Adaptive Biotechnologies’ products and pipeline are focused on two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Its MRD product aids in diagnosing cancer, while its Immune Medicine product helps diagnose autoimmune disorders and infectious diseases. The ultimate goal is to develop personalized immune-driven clinical products for each patient.

On Tuesday, April 2, 2024, after the market closes at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, Adaptive Biotechnologies will be hosting a business update conference call and webcast. The live audio of the webcast will be available on the “Investors” section of the company website at www.adaptivebiotech.com. The webcast will also be archived for replay within 24 hours after the event.

For inquiries from investors, Karina Calzadilla, Vice President of Investor Relations, can be reached at investors@adaptivebiotech

Leave a Reply